

1 **Association of *IFNAR2* rs2236757 and *OAS3* rs10735079 polymorphisms with**
2 **susceptibility to COVID-19 infection and severity**

3

4

5

6 Mohammad Abdelhafez¹, Abedelmajeed Nasereddin², Omar Abu Shamma¹, Rajaa Abed¹,
7 Raghida Sinnokrot¹, Omar Marof¹, Tariq Heif¹, Zaid Erekat¹, Amer Al-Jawabreh ³, Suheir
8 Erekat^{2*}

9

10

11 ¹Faculty of Medicine, Al-Quds University, Abu Deis, East Jerusalem, Palestine.

12

13 ² Biochemistry and Molecular Biology Department, Faculty of Medicine, Al-Quds University,
14 Abu Deis, East Jerusalem, Palestine.

15

16 ³Department of Medical Laboratory Sciences, Faculty of Allied Health Sciences, Arab American
17 University, Jenin, Palestine.

18

19

20

21 ***Corresponding Author:** Suheir Erekat sereqat@staff.alquds.edu

22

23

24

25

26 **Running title:** Human genetic factors in COVID-19

27

28

29

30

31 **Abstract:**

32 The clinical course and severity of COVID-19 vary among patients. This study aimed to
33 investigate the association of the interferon receptor (*IFNAR2*) rs2236757 and oligoadenylate
34 synthetase 3 (*OAS3*) rs10735079 gene polymorphisms with risk of COVID-19 infection and
35 severity among Palestinian patients. The study was conducted between April and May 2021 on
36 154 participants that divided into three groups: the control group (RT-PCR-negative, n=52), the
37 community cases group (RT-PCR-positive, n= 70) and the critically ill cases (ICU group; n=32).
38 Genotyping of the studied polymorphisms was conducted by amplicon-based next-generation
39 sequencing.

40 The genotype distribution of the *IFNAR2* rs2236757 was significantly different among the study
41 groups ($P = 0.001$), while no significant differences were observed in the distribution of *OAS3*
42 rs10735079 genotypes ($P = 0.091$). Logistic regression analysis adjusted for possible
43 confounding factors revealed a significant association between the risk allele rs2236757A and
44 critical COVID-19 illness ($P < 0.025$). Among all patients, the rs2236757GA carriers were more
45 likely to have sore throat (OR, 2.52 (95% CI 1.02-6.24); $P = 0.011$); the risk allele rs2236757A
46 was associated with dyspnea (OR, 4.70 (95% CI 1.80-12.27); $P < 0.001$), while the rs10735079A
47 carriers were less prone to develop muscle aches (OR, 0.34 (95% CI 0.13-0.88); $P = 0.0248$) and
48 sore throat (OR, 0.17 (95% CI 0.05-0.55); $P < 0.001$). In conclusion, our results revealed that the
49 rs2236757A variant was associated with critical COVID-19 illness and dyspnea, whereas the
50 rs10735079A variant was protective for muscle aches and sore throat.

51

52 **Key Words:** SARS-CoV-2; COVID-19; SNPs; *OAS3*; *IFNAR2*.

53

54 **Introduction**

55 The Coronavirus disease 2019 (COVID-19) is a respiratory and systemic disease caused by
56 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first reported in Wuhan, China,
57 in December 2019 and then rapidly spread across the globe. Worldwide, more than 613 million
58 coronavirus patient was reported with more than 6.5 million of total deaths (Worldometers.info:
59 Dover, Delaware, U.S.A) accessed date 10-09-2022). It is transmitted predominately from person
60 to person mainly through inhalation of small, exhaled respiratory droplets containing infectious
61 virions [1]. The clinical manifestations range from asymptomatic, to severe, life-threatening
62 acute respiratory distress syndrome (ARDS), multi-organ failure, and death [2]. The major
63 symptoms of the disease include fever, cough, fatigue, sore throat, headache, and shortness of
64 breath, with progression to pneumonia [3]. Households are favorable venues for viral
65 transmission, where family members may crowd and be in close contact without following social
66 distancing rules or using masks. Although all household contacts of a positive COVID-19 patient
67 are exposed to the virus, not all get infected.

68 Previous reports showed that male gender, elder age group, and the existence of comorbidities
69 (e.g., cardiovascular, pulmonary, and renal diseases) are risk factors for COVID-19 infection [4].
70 However, the wide range of the reported symptoms suggested that genetic risk factors may also
71 have a crucial role in disease progression. Although the virus's new mutations have emerged
72 (e.g., UK, South Africa, and India), few studies described the inter-individual genetic differences
73 in the immune response to these new versions of coronavirus.

74 It was reported that variants of the angiotensin converting enzyme 2 (ACE2) gene encode the
75 cellular receptor for SARS-CoV-2 and polymorphisms of serine protease TMPRSS2 affect viral
76 entry and invasion and thus increase COVID-19 severity [5,6]. Moreover, a genome-wide
77 association study (GWAS) conducted in the UK compared the genetic variants in critically ill
78 patients (n= 2244) with severe COVID-19 to variants found in a healthy control group. The study
79 revealed significant associations between the severity of COVID-19 and the genetic variants in
80 five loci including chromosome 3p21.31, spanning the *SLC6A20*, *LZTFL1*, *CCR9*, *FYCO1*,
81 *CXCR6*, and *XCR1* genes; chromosome 12q24.13, in the *OAS* gene cluster; chromosome
82 19p13.2, near tyrosine kinase 2 (TYK2); chromosome 19p13.3, within dipeptidyl peptidase 9
83 (*DPP9*); chromosome 21q22.1, within the interferon receptor gene *INFAR2*. Of these genes,

84 *IFNAR2* and *OAS*, are important in the early stages of the disease, whereas the *DPP9*, *TYK2*, and
85 *CCR2* genes drive inflammatory processes in the late stages of critical COVID-19 [7].

86 . It is well-established that SARS-CoV-2 infection activates innate and adaptive immune
87 response, failure of this system and dysregulated massive pro-inflammatory host response would
88 cause harmful tissue damage [8].

89 In this context, the study objective was to investigate the association of four SNPs (*IFNAR2*
90 rs2236757, *DPP9* rs2109069, *OAS3* rs10735079, and *LZTFL1* rs73064425 variants), with the
91 susceptibility to COVID-19 infection in Palestinian household contacts and their associations
92 with the clinical manifestations and severity of COVID 19, using amplicon-based next
93 generation sequencing (NGS).

94

95 **Materials and methods**

96 **Study participants**

97 The study participants were recruited from 30 household Palestinian families- living in different
98 cities in the West Bank, Palestine- between April and May 2021. The family was included in the
99 study if it has at least one clinically and laboratory-confirmed COVID-19 case and one
100 laboratory-negative household contact with no COVID-19 symptoms. We divided all family
101 members into two groups: infected cases (community cases group) or uninfected household
102 contacts (control group). An infected case was defined by having a positive RT-PCR test
103 regardless of having symptoms or not and regardless of being a primary or secondary case. An
104 uninfected contact was defined as a family member who had unprotected contact with a positive
105 case, lives at the same place, stayed asymptomatic for ten days after symptoms onset or RT-PCR
106 diagnosis of a positive case; and was tested negative by RT-PCR. Additionally, we consecutively
107 enrolled patients from an intensive care unit (ICU) -at the Palestinian Medical Complex,
108 Ramallah - due to critical COVID-19 illness (ICU cases).

109 We excluded individuals who received COVID-19 vaccination, regardless of the type of the
110 vaccine. Patients' data, including demographic information, symptoms, RT-PCR test result, and
111 comorbidities, were collected via a well-structured questionnaire supervised by health care
112 personnel.

113

114

115 **Sampling, DNA extraction, and genotyping**

116 Blood-sample (five ml) was collected in an EDTA tube from all study participants. The DNA
117 was extracted from each blood sample (200 μ l) using a genomic QIAamp DNA purification kit
118 as per the manufacturer's instructions (Qiagen, Hilden, Germany) and kept frozen (-20C) for
119 further analysis. All DNA samples were genotyped for the rs2236757 of *IFNAR2*, rs2109069 of
120 *DPP9*, rs10735079 of *OAS3*, and rs73064425 of the *LZTFL1* gene using amplicon-based NGS
121 (NGS). Briefly, two primers (forward and reverse) were used to target each single nucleotide
122 polymorphism (SNP) as described in Table S1. All primers were modified with over-hanged
123 Illumina adaptor sequences at the 5' ends (bolded, Table S1), targeting partial sequences of the
124 studied genes. The final product size for each targeted gene was mentioned in Table S1.

125 The PCR product was visualized by 1.5% agarose gel, cleaned by Agencourt AMPure XP system
126 (X1, A63881; Beckman Coulter Genomics, Indianapolis, IN, USA), and eluted into a final
127 volume of 25 μ l. All purified samples were amplified by dual indices PCR to barcode each
128 sample using Nextera XT Index Kit (Illumina, San Diego, CA, USA); Five μ l from each
129 barcoded sample were pooled together, cleaned again by Agencourt AMPure XP system (X1),
130 and eluted in 50 μ l elution buffer. The concentrations of the prepared Libraries were tested by
131 Qubit® Fluorometer (Invitrogen, Carlsbad, CA, USA). A concentration of 4 nM was used with a
132 target of 20k reads for each sample. Deep sequencing was done by NextSeq 500/550 machine
133 using 150-cycle Mid Output Kit (Illumina, San Diego, CA, USA).

134

135 **Bioinformatics and Sequence Analysis**

136 The sequencing data were uploaded to the Galaxy web platform, and we used the public server at
137 "usegalaxy.org" to analyze the obtained DNA sequences [9]. The workflow of filtration included
138 Illumina adaptor trim and quality selection of Q > 20 with a minimal read length of 100 bp. We
139 used eight virtual probe sequences to identify the targeted variants (Table S1). Ultimately, the
140 genotypes were determined based on the ratio between the read counts for wild-type and minor
141 alleles. SNPs were included in the study if they passed our quality measures; Hardy–Weinberg
142 equilibrium (HWE) > 0.05 and genotyping rate > 95%.

143

144

145

146 **Statistical Analysis**

147 We performed the statistical analysis using the SPSS package, version 26.0 (SPSS, Inc.,
148 Chicago, IL, USA) and the R environment v.4.1.3. All tests were two-tailed, and we considered
149 P-value < 0.05 significant unless specified. We tested for The Hardy-Weinberg equilibrium
150 (HWE) for all SNPs using the “SNPassoc” package [10]. Moreover, we examined the genetic
151 susceptibility of SARS-CoV-2 and the genetic association with the critical COVID-19 illness by
152 comparing the community patients with the controls, and the ICU patients with the controls,
153 respectively, using five genetic models (co-dominant, dominant, over-dominant, recessive, and
154 additive). Models were adjusted for patient characteristics; age, gender, smoking, history,
155 hypertension, diabetes mellitus, and coronary artery diseases using the “SNPassoc” package.
156 Adjusted odds ratios (ORs) with the associated 95% confidence interval (CI) were calculated for
157 each model. The same models were used to investigate Gene-(Symptoms/Signs) associations.
158 The best model for each SNP was selected using the Akaike information criterion [11]. We used
159 Bonferroni correction for multiple comparisons to correct statistical significance ($P < 0.05$,
160 divided by the number of analyzed SNPs) [12,13]. Ultimately, we investigated for any potential
161 gene-gene interaction.

162

163 **Results**

164 **Characteristics of Study Participants**

165 A total of 154 Palestinians were included in this study and divided into three groups; COVID-19
166 infected patients (Community cases group, n=70), uninfected household contacts (Control group,
167 n=52) and critically ill COVID -19 patients (ICU group, n=32). In each group, the median (IQR)
168 age was 28 (27), 24.5 (21.5), and 61 years (27). The characteristics and comorbidities of each
169 study group are shown in Table 1. The median age, the prevalence of smoking, diabetes mellitus
170 (DM), hypertension, and coronary artery disease (CAD) were significantly higher in the ICU
171 group ($P < 0.05$). The clinical characteristics of COVID-19 patients in the community and ICU
172 groups with signs and symptoms frequencies are presented in Table 2. The percentage of
173 symptomatic patients was 93% in the community cases group, whereas 100% in the ICU group.
174 The frequency of fatigability, headache, and loss of taste and/ or smell was significantly higher
175 in the community cases group ($P < 0.05$). However, dyspnea and cough were more frequent in
176 the ICU group ($P < 0.05$).

177 **Genotyping of *IFNAR2* rs2236757 and *OAS3* rs10735079**

178 The minor allele frequency (MAF) of the *IFNAR2* rs2236757A and the *OAS3* rs10735079A was
179 27% and 50%, respectively. The frequency and genotypes distribution of the *IFNAR2*
180 rs2236757A and the *OAS3* rs10735079A among the three study groups are provided in Table 3.
181 The *IFNAR2* rs2236757 genotypes distribution was significantly variable among the study
182 groups ($P = 0.001$), while no significant differences were observed in the distribution of *OAS3*
183 rs10735079 genotypes ($P = 0.091$). The two SNPs; *DPP9* rs2109069, and the *LZTFL1*
184 rs73064425, were excluded from the study due to deviation from the HWE (i.e., $P < 0.05$) and
185 the low genotyping rate (i.e., $<95\%$).

186

187

188 ***IFNAR2* rs2236757 and *OAS3* rs10735079 polymorphisms and susceptibility to COVID-19** 189 **infection**

190 Logistic regression analysis under five genetic models adjusted for age, sex, smoking history,
191 DM, hypertension, and CAD was used to investigate the role of *IFNAR2* rs2236757 and *OAS3*
192 rs10735079 polymorphisms in the susceptibility of COVID-19 infection and severity, the
193 community cases group was compared to the control group and the ICU group was compared to
194 the control group. As shown in Table 4, none of the studied polymorphisms have a statistically
195 significant association with SARS-CoV-2 infection among community cases ($P > 0.025$) after
196 Bonferroni correction. However, the risk allele rs2236757A of the *IFNAR2* gene was
197 significantly associated with critical COVID-19 illness in all genetic models ($P < 0.025$) except
198 for the recessive ($P = 0.4$). According to the Akaike information criterion, the dominant model
199 was the best to explain the association (OR, 8.65 (95% CI 1.60-46.68); $P = 0.005$). No
200 significant relationship between the *OAS3* rs10735079 polymorphism and critical COVID-19
201 illness was observed ($P > 0.025$; Table S2).

202

203 **Association of *IFNAR2* rs2236757 and *OAS3* rs10735079 polymorphisms with COVID-19** 204 **signs and symptoms**

205 Logistic regression analysis under five genetic models adjusted for age, sex, smoking history,
206 DM, hypertension, and CAD was used to investigate the association of *IFNAR2* rs2236757 and
207 *OAS3* rs10735079 polymorphisms with COVID-19 signs and symptoms.

208 For all patients (the community cases group and ICU group), the *IFNAR2* rs2236757 GA carriers
209 were more likely to have a sore throat (OR, 2.52 (95% CI 951.02-6.24); $P = 0.011$) (Table 5). In
210 addition, patients who developed dyspnea were more likely to have the risk allele rs2236757A;
211 the association was best explained by the additive model (OR, 4.70 (95% CI 1.80-12.27); $P <$
212 0.001). On the other hand, patients with the risk allele rs10735079A were less prone to develop
213 muscle aches (OR, 0.34 (95% CI 0.13-0.88); $P = 0.0248$) and sore throat (OR, 0.17 (95% CI
214 0.05-0.55); $P < 0.001$), both associations were best explained by the recessive model (Table 5).
215 Further analysis was performed to compare the community cases group with the control group
216 and the ICU group with the control group as shown in Table 6. None of the community cases
217 group was homozygous for the risk allele *IFNAR2* rs2236757A (Table 6). However, the risk
218 allele rs2236757A was associated with loss of taste or smell (OR, 3.57 (95% CI 1.19-10.72); $P =$
219 0.019), muscle aches (OR, 3.65 (95% CI 1.12-11.86); $P = 0.025$), and dyspnea (OR, 4.84 (95%
220 CI 1.45-16.13); $P = 0.006$). We also found that patients with sore throat in the community cases
221 group were unlikely to be homozygous (AA) for the risk allele rs10735079A of *OAS3*; the
222 association was only explained by the recessive model (OR, 0.19 (95% CI 0.05-0.79); $P =$
223 0.012). Among the ICU group, muscle aches were the only symptoms that had a genetic
224 association; patients with the risk allele rs10735079A were less prone to muscle aches in two
225 models (recessive and additive), and best explained by the additive (OR, 0.22 (0.05-0.99); $P =$
226 0.014) (Table 6). We tested gene-gene interaction in all models that had a significant association
227 with the clinical manifestations; we did not find a statistically significant interaction between the
228 SNPs. Still, heterozygous rs2236757 (GA) carriers with sore throat were less likely to be
229 homozygous (AA) for the risk allele rs10735079A (OR, 0.06 (95% CI 0.01-0.57)) (data not
230 shown).

231

232

233

234

235

236

237

238

239 Discussion

240 COVID-19 manifestations are variable among patients, even amongst household members.
241 Before the introduction of the COVID-19 vaccination, 33% of people with SARS-CoV-2
242 infection were reported to be asymptomatic [14]. Wu Z and McGoogan JM reported mild
243 COVID-19 infection in 81% of the patients, severe disease in 14%, and critical illness in 5%[15].
244 Age, comorbidities, sex, and socioeconomic background play an essential role in COVID-19
245 severity [16–19]. Moreover, novel host genetic factors associated with COVID-19 infection and
246 severity were identified through the collaborated community of human genetics researchers [20].
247 In the current study, we found that the risk allele *IFNAR2* rs2236757A has a significant
248 association with the critical COVID-19 illness. Such an association was not present for the
249 rs10735079 variant. The rs2236757A variant was found to be related to the critical COVID-19
250 illness in genome-wide significant associations. Additionally, *IFNAR2* has a causal role from a
251 Mendelian randomization result; increased expression of the interferon receptor subunit IFNAR2
252 reduced the odds of severe COVID-19 ($P = 0.0043$) [7]. Type 1 interferons bind IFNAR2, which
253 leads to activation and signal transduction, involving the JAK-STAT pathway [21].
254 Consequently, this pathway initiates antiviral activity from the target cells and induces apoptosis
255 in infected cells [22]. The role of *IFNAR2* expression was further replicated in other Mendelian
256 randomization studies [23–25]. OAS is a family of antiviral proteins consisting of four members,
257 OAS1, OAS2, OAS3, and OAS-like protein [26]. Both, Interferon and virus infection stimulate
258 the transcription of *OAS* genes in the cell [27,28]. Ribonuclease L is activated through the
259 OAS1- to 3 proteins; products with 2'-5' oligoadenylate synthetase activity. Ribonuclease L
260 activation leads to the degradation of the cellular and viral RNA, resulting in the inhibition of
261 protein synthesis and terminating viral replication [29–31]. The variant rs10735079 lies in the
262 interferon-inducible *OAS* gene cluster (*OAS1*, *OAS2*, and *OAS3*) and was associated with critical
263 COVID-19 illness ($P = 1.65 \times 10^8$) in genome-wide significant associations [7]. However, a
264 similar association was not present in our study.

265 Different symptom clusters have a difference in in-hospital outcomes [32]. Reis et al. reported in
266 a cross-sectional study with nearly 60,000 COVID-19 patients that fever and breathing difficulty
267 increased the chances of hospitalization and death. However, running nose, sore throat, diarrhea,
268 and headache were associated with lower odds of hospitalization and death; they concluded that
269 these symptoms indicate a protective effect [33]. Sadeghifar et al. showed in their binary logistic

270 regression model of disease outcome by disease symptoms that shortness of breath and abnormal
271 chest radiographic findings were predictors of higher mortality. Conversely, patients with sore
272 throats signified lower mortality [34]. Moreover, Chang et al. indicated that body temperature,
273 chills, initial chest X-ray findings, and the presence of diabetes were significant predictors of
274 progression to the severe stage of COVID-19 [35].

275 Studies that evaluate the role of human genetics in developing the different signs and symptoms
276 of COVID-19 are scarce. Williams et al. studied 3261 same-sex twins to investigate the presence
277 of heritable components in developing the different symptoms of COVID-19. They found
278 heritability elements for delirium, diarrhea, fatigue, anosmia, and meal skipping [36].

279 Herein, we investigated the role of the rs2236757 and the rs10735079 variants in developing the
280 different signs and symptoms of COVID-19 in all COVID-19 patients, and in the community
281 patients and ICU patients, separately. Our results indicated that patients with the risk allele
282 rs2236757A were more likely to have dyspnea and sore throat. Among the community patients,
283 the risk allele rs2236757A was found to be associated with dyspnea, loss of taste or smell, and
284 muscle aches. Surprisingly, patients with the risk allele rs10735079A were unlikely to have a
285 sore throat or muscle aches; in particular, the community cases group was less likely to have a
286 sore throat, and the ICU subgroup was less prone to muscle aches. Given that the risk allele
287 rs10735079A was found to be associated with critical COVID-19 illness in multiple previous
288 studies [7,37], the inverse association of the risk allele rs10735079A with having a sore throat
289 might be consistent with Reis et al. and Sadeghifar et al. findings indicating that sore throat
290 might have a protective effect against COVID-19 hospitalization and death [33,34].

291 It was reported that Interferon-beta inhibits SARS-CoV-2 virus replication in vitro [38].
292 However, clinical trials did not reveal a clear benefit from interferon therapy for hospitalized
293 patients with severe COVID-19 [39–42]. Yet, a systematic review of five clinical trials
294 concluded that early administration of Interferon-beta combined with other antiviral drugs is
295 promising [43]. Low expression of *IFNAR2* has a causal role in the progression to critical
296 COVID-19 illness [7]; our study was in line with the Pairo-Castineira et al. study which
297 demonstrated that rs2236757A was associated with the severity of COVID-19 illness [7].
298 Therefore, a randomized controlled trial that examines the role of interferon therapy in COVID-
299 19 patients who have the rs2236757A variant or other reported variants will help to understand
300 the role of interferon therapy and its benefits.

301 Our study is limited by the small number of included participants, which was in part due to the
302 newly emerged variants of the SARS-CoV-2 virus; we could not continue recruiting patients
303 when the new SARS-CoV-2 variants became prevalent in Palestine, as different variants may
304 have different manifestations and pathogenesis [44,45]. Moreover, the COVID-19 vaccination
305 was started by the government, which can alter the results. The limited number of patients in the
306 present study may explain the lack of association between the rs10735079 polymorphism and the
307 critical COVID-19 illness. Nonetheless, targeting families strengthen the certainty of adequate
308 exposure to the SARS-CoV-2 virus in the control group. Additionally, the present study is the
309 first in Palestine and one of the few studies that investigated the role of human genetic factors in
310 COVID-19 signs and symptoms. In Conclusion, our study revealed that the *IFNAR2* rs2236757A
311 variant is associated with critical COVID-19 illness. the risk allele rs2236757A was associated
312 with dyspnea and sore throat while patients with the risk allele rs10735079A were unlikely to
313 have a sore throat or muscle aches. Our study may provide preliminary results for further genetic
314 association studies to clarify the role of human genetics in different signs and symptoms of
315 COVID-19 and to enhance our understanding of the pathophysiology of SARS-CoV-2 infection
316 and its complications.

317

318 **Acknowledgements:**

319 The authors would like to thank all the study participants

320

321 **Authors' contributions:**

322 SE and AN designed and supervised the experiments, edited and revised the manuscript. MA
323 analyzed the data and wrote the first draft of the manuscript. MA, OA, RA, RS, OM, TH, and ZE
324 extracted the DNA and performed the experiments. AJ involved in patient sampling and data
325 collection. All authors read and approved the final manuscript.

326 **Funding**

327 This research received no specific grant from any funding agency.

328 **Availability of data and materials:**

329 Data used in this research are available from the corresponding author on request

330

331

332 **Declarations**

333 **Ethics approval and consent to participate**

334 The study procedure was approved by the research ethics committee at Al-Quds University
335 (184/REC/2021), with implied consent from all participants.

336 **Competing interests**

337 The authors declare that no competing interests exist.

338

339 **References:**

- 340 1. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease
341 (COVID-19) outbreak. *J Autoimmun.* 2020;109. doi:10.1016/J.JAUT.2020.102433
- 342 2. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19:
343 consider cytokine storm syndromes and immunosuppression. *The Lancet.* 2020;395:
344 1033–1034. doi:10.1016/S0140-6736(20)30628-0
- 345 3. Zhou P, Yang X lou, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak
346 associated with a new coronavirus of probable bat origin. *Nature.* 2020;579: 270–273.
347 doi:10.1038/S41586-020-2012-7
- 348 4. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for
349 mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort
350 study. *The Lancet.* 2020;395: 1054–1062. doi:10.1016/S0140-6736(20)30566-
351 3/ATTACHMENT/E61DC4CE-2C32-4FA9-85D7-95911E7D3B94/MMC1.PDF
- 352 5. Cao Y, Li L, Feng Z, Wan S, Huang P, Sun X, et al. Comparative genetic analysis of the
353 novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations.
354 *Cell Discovery* 2020 6:1. 2020;6: 1–4. doi:10.1038/s41421-020-0147-1
- 355 6. Asselta R, Paraboschi EM, Mantovani A, Duga S. ACE2 and TMPRSS2 variants and
356 expression as candidates to sex and country differences in COVID-19 severity in Italy.
357 *Aging.* 2020;12: 10087–10098. doi:10.18632/AGING.103415
- 358 7. Pairo-Castineira E, Clohisey S, Klaric L, Bretherick AD, Rawlik K, Pasko D, et al.
359 Genetic mechanisms of critical illness in COVID-19. *Nature* 2020 591:7848. 2020;591:
360 92–98. doi:10.1038/s41586-020-03065-y
- 361 8. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected
362 with 2019 novel coronavirus in Wuhan, China. *Lancet.* 2020;395: 497–506.
363 doi:10.1016/S0140-6736(20)30183-5
- 364 9. Afgan E, Baker D, van den Beek M, Blankenberg D, Bouvier D, Čech M, et al. The
365 Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2016
366 update. *Nucleic Acids Res.* 2016;44: W3–W10. doi:10.1093/NAR/GKW343
- 367 10. González JR, Armengol L, Solé X, Guinó E, Mercader JM, Estivill X, et al. SNPAssoc: an
368 R package to perform whole genome association studies. *Bioinformatics.* 2007;23: 654–
369 655. doi:10.1093/BIOINFORMATICS/BTM025
- 370 11. Bozdogan H. Model selection and Akaike’s Information Criterion (AIC): The general
371 theory and its analytical extensions. *Psychometrika* 1987 52:3. 1987;52: 345–370.
372 doi:10.1007/BF02294361

- 373 12. carboni CB-S in onore del professore salvatore ortu, 1935 undefined. Il calcolo delle
374 assicurazioni su gruppi di teste. ci.nii.ac.jp. [cited 16 Jul 2022]. Available:
375 <https://ci.nii.ac.jp/naid/20001029336/>
- 376 13. Scienze CB-P del RIS di, 1936 undefined. Teoria statistica delle classi e calcolo delle
377 probabilita. cir.nii.ac.jp. [cited 16 Jul 2022]. Available:
378 <https://cir.nii.ac.jp/crid/1570009749360424576>
- 379 14. Oran DP, Topol EJ. The Proportion of SARS-CoV-2 Infections That Are Asymptomatic :
380 A Systematic Review. *Ann Intern Med.* 2021;174: 655–662. doi:10.7326/M20-6976
- 381 15. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus
382 Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases
383 From the Chinese Center for Disease Control and Prevention. *JAMA.* 2020;323: 1239–
384 1242. doi:10.1001/JAMA.2020.2648
- 385 16. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the
386 severity of coronavirus disease 2019: a model-based analysis. *Lancet Infect Dis.* 2020;20:
387 669–677. doi:10.1016/S1473-3099(20)30243-7
- 388 17. Stokes EK, Zambrano LD, Anderson KN, Marder EP, Raz KM, el Burai Felix S, et al.
389 Coronavirus Disease 2019 Case Surveillance - United States, January 22-May 30, 2020.
390 *MMWR Morb Mortal Wkly Rep.* 2020;69: 759–765. doi:10.15585/MMWR.MM6924E2
- 391 18. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al.
392 Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients
393 Hospitalized With COVID-19 in the New York City Area. *JAMA.* 2020;323: 2052–2059.
394 doi:10.1001/JAMA.2020.6775
- 395 19. Magesh S, John D, Li WT, Li Y, Mattingly-App A, Jain S, et al. Disparities in COVID-19
396 Outcomes by Race, Ethnicity, and Socioeconomic Status: A Systematic-Review and
397 Meta-analysis. *JAMA Netw Open.* 2021;4.
398 doi:10.1001/JAMANETWORKOPEN.2021.34147
- 399 20. Niemi MEK, Karjalainen J, Liao RG, Neale BM, Daly M, Ganna A, et al. Mapping the
400 human genetic architecture of COVID-19. *Nature* 2021 600:7889. 2021;600: 472–477.
401 doi:10.1038/s41586-021-03767-x
- 402 21. Novick D, Cohen B, Rubinstein M. The human interferon $\alpha\beta$ receptor: Characterization
403 and molecular cloning. *Cell.* 1994;77: 391–400. doi:10.1016/0092-8674(94)90154-6
- 404 22. Taniguchi T, Takaoka A. The interferon-alpha/beta system in antiviral responses: a
405 multimodal machinery of gene regulation by the IRF family of transcription factors. *Curr*
406 *Opin Immunol.* 2002;14: 111–116. doi:10.1016/S0952-7915(01)00305-3
- 407 23. Gaziano L, Giambartolomei C, Pereira AC, Gaulton A, Posner DC, Swanson SA, et al.
408 Actionable druggable genome-wide Mendelian randomization identifies repurposing
409 opportunities for COVID-19. *Nature Medicine* 2021 27:4. 2021;27: 668–676.
410 doi:10.1038/s41591-021-01310-z
- 411 24. Liu D, Yang J, Feng B, Lu W, Zhao C, Li L. Mendelian randomization analysis identified
412 genes pleiotropically associated with the risk and prognosis of COVID-19. *Journal of*
413 *Infection.* 2021;82: 126–132. doi:10.1016/J.JINF.2020.11.031
- 414 25. Hernández Cordero AI, Li X, Milne S, Yang CX, Bossé Y, Joubert P, et al. Multi-omics
415 highlights ABO plasma protein as a causal risk factor for COVID-19. *Hum Genet.*
416 2021;140: 969–979. doi:10.1007/S00439-021-02264-5/FIGURES/3
- 417 26. Sadler AJ, Williams BRG. Interferon-inducible antiviral effectors. *Nat Rev Immunol.*
418 2008;8: 559–568. doi:10.1038/NRI2314

- 419 27. P B, M V, D P, M R, J C. Interferon-responsive regulatory elements in the promoter of the
420 human 2',5'-oligo(A) synthetase gene. *Mol Cell Biol.* 1987;7: 4498–4504.
421 doi:10.1128/MCB.7.12.4498-4504.1987
- 422 28. Melchjorsen J, Kristiansen H, Christiansen R, Rintahaka J, Matikainen S, Paludan SR, et
423 al. Differential regulation of the OASL and OAS1 genes in response to viral infections. *J*
424 *Interferon Cytokine Res.* 2009;29: 199–207. doi:10.1089/JIR.2008.0050
- 425 29. Baglioni C, Minks MA, Clercq E de. Structural requirements of polynucleotides for the
426 activation of (2' - 5')An polymerase and protein kinase. *Nucleic Acids Res.* 1981;9:
427 4939–4950. doi:10.1093/NAR/9.19.4939
- 428 30. Dong B, Silverman RH. A bipartite model of 2-5A-dependent RNase L. *J Biol Chem.*
429 1997;272: 22236–22242. doi:10.1074/JBC.272.35.22236
- 430 31. Clemens MJ, Williams BRG. Inhibition of cell-free protein synthesis by pppA2' p5' A2'
431 p5' A: a novel oligonucleotide synthesized by interferon-treated L cell extracts. *Cell.*
432 1978;13: 565–572. doi:10.1016/0092-8674(78)90329-X
- 433 32. Millar JE, Neyton L, Seth S, Dunning J, Merson L, Murthy S, et al. Distinct clinical
434 symptom patterns in patients hospitalised with COVID-19 in an analysis of 59,011
435 patients in the ISARIC-4C study. *Scientific Reports* 2022 12:1. 2022;12: 1–13.
436 doi:10.1038/s41598-022-08032-3
- 437 33. dos Reis EC, Rodrigues P, de Jesus TR, de Freitas Monteiro EL, Virtuoso Junior JS,
438 Bianchi L. Risk of hospitalization and mortality due to COVID-19 in people with obesity:
439 An analysis of data from a Brazilian state. *PLoS One.* 2022;17.
440 doi:10.1371/JOURNAL.PONE.0263723
- 441 34. Sadeghifar J, Jalilian H, Momeni K, Delam H, Sheleme T, Rashidi A, et al. Outcome
442 evaluation of COVID-19 infected patients by disease symptoms: a cross-sectional study in
443 Ilam Province, Iran. *BMC Infect Dis.* 2021;21: 1–5. doi:10.1186/S12879-021-06613-
444 7/TABLES/4
- 445 35. Chang MC, Park YK, Kim BO, Park D. Risk factors for disease progression in COVID-19
446 patients. *BMC Infect Dis.* 2020;20: 1–6. doi:10.1186/S12879-020-05144-X/FIGURES/1
- 447 36. Williams FMK, Freidin MB, Mangino M, Couvreur S, Visconti A, Bowyer RCE, et al.
448 Self-Reported Symptoms of COVID-19, Including Symptoms Most Predictive of SARS-
449 CoV-2 Infection, Are Heritable. *Twin Res Hum Genet.* 2020;23: 316–321.
450 doi:10.1017/THG.2020.85
- 451 37. Niemi MEK, Karjalainen J, Liao RG, Neale BM, Daly M, Ganna A, et al. Mapping the
452 human genetic architecture of COVID-19. *Nature* 2021 600:7889. 2021;600: 472–477.
453 doi:10.1038/s41586-021-03767-x
- 454 38. Clementi N, Ferrarese R, Criscuolo E, Diotti RA, Castelli M, Scagnolari C, et al.
455 Interferon- β -1a Inhibition of Severe Acute Respiratory Syndrome-Coronavirus 2 In Vitro
456 When Administered After Virus Infection. *J Infect Dis.* 2020;222: 722–725.
457 doi:10.1093/INFDIS/JIAA350
- 458 39. H P, R P, AM H-R, MP P, V S, Q AK, et al. Repurposed Antiviral Drugs for Covid-19 -
459 Interim WHO Solidarity Trial Results. *N Engl J Med.* 2021;384: 497–511.
460 doi:10.1056/NEJMOA2023184
- 461 40. Davoudi-Monfared E, Rahmani H, Khalili H, Hajiabdolbaghi M, Salehi M, Abbasian L, et
462 al. A Randomized Clinical Trial of the Efficacy and Safety of Interferon β -1a in Treatment
463 of Severe COVID-19. *Antimicrob Agents Chemother.* 2020;64. doi:10.1128/AAC.01061-
464 20

- 465 41. Kalil AC, Mehta AK, Patterson TF, Erdmann N, Gomez CA, Jain MK, et al. Efficacy of
466 interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults
467 with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet*
468 *Respir Med*. 2021;9: 1365–1376. doi:10.1016/S2213-2600(21)00384-2
- 469 42. Monk PD, Marsden RJ, Tear VJ, Brookes J, Batten TN, Mankowski M, et al. Safety and
470 efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2
471 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Respir*
472 *Med*. 2021;9: 196–206. doi:10.1016/S2213-2600(20)30511-7
- 473 43. Nakhband A, Fakhari A, Azizi H. Interferon-beta offers promising avenues to COVID-19
474 treatment: a systematic review and meta-analysis of clinical trial studies. *Naunyn*
475 *Schmiedebergs Arch Pharmacol*. 2021;394: 829–838. doi:10.1007/S00210-021-02061-X
- 476 44. Menni C, Valdes AM, Polidori L, Antonelli M, Penamakuri S, Nogal A, et al. Symptom
477 prevalence, duration, and risk of hospital admission in individuals infected with SARS-
478 CoV-2 during periods of omicron and delta variant dominance: a prospective
479 observational study from the ZOE COVID Study. *Lancet*. 2022;399: 1618–1624.
480 doi:10.1016/S0140-6736(22)00327-0
- 481 45. Bálint G, Vörös-Horváth B, Széchenyi A. Omicron: increased transmissibility and
482 decreased pathogenicity. *Signal Transduction and Targeted Therapy* 2022 7:1. 2022;7: 1–
483 3. doi:10.1038/s41392-022-01009-8

Table 1: Baseline characteristics and comorbidities.

	Community patients (N=70)	ICU patients (N=32)	Control (N=52)	P- Value
M: F	32:38	19:13	33:19	0.124
Age †	28 [21.5- 48.5]	61 [41-68]	24.5 [20.25- 41.75]	< 0.001 *
Smoking	15.70%	31.30%	30.80%	0.117
DM	5.70%	25%	3.80%	0.009
Hypertension	4.30%	43.80%	3.80%	0.001
CAD	4.30%	40.60%	0%	0.001

† Median [25th -75th percentile]. * P-value was obtained by Independent-Samples Kruskal-Wallis Test. P < 0.05 was considered significant. M, male; F, female; DM, diabetes mellitus; CAD, coronary artery disease; ICU, intensive care unit.

Table 2: Signs and symptoms of COVID-19 in the community cases and the intensive care unit groups

	Community cases group(70)		ICU group(32)		P-value
	N	%	N	%	
Symptomatic	64	93	32	100	0.118
Runny nose	34	49	7	22	0.009
Fatigue	52	75	11	36	0.001
Headache	49	71	10	33	0.001
Fever	43	62	21	70	0.463
Loss of smell/ taste	45	65	12	40	0.02
Muscle ache	42	61	21	68	0.51
Diarrhea	24	35	6	19	0.119
Sore throat	27	39	9	30	0.385
Cough	33	49	22	71	0.037
Dyspnea	24	35	27	87	0.001

P < 0.05 was considered significant. ICU, intensive care unit.

Table 3: Genotypes distribution of the *IFNAR2* rs2236757 and *OAS3* rs10735079 among the studied groups

SNP	Alleles (major/minor)	Minor allele frequency N (%)	Genotypes	Community cases group	ICU group	Control group	P- value
rs2236757 (<i>IFNAR2</i>)	G/A	83 (26.9)	AA	0	6	2	0.001
			GA	35	15	17	
			GG	35	11	33	
rs10735079 (<i>OAS3</i>)	G/A	153 (50.3)	AA	20	11	12	0.091
			GA	31	8	28	
			GG	19	13	10	

Person's chi-squared test, P < 0.05 was considered significant.

Table 4: Association of *IFNAR2* rs2236757 polymorphism with COVID-19 infection among the studied groups

SNP	Genetic model	Control	Community cases	ICU	Community cases Vs. Controls: OR (95% CI); P-value	ICU group Vs. Control: OR (95% CI); P-value
<i>rs2236757</i> (<i>IFNAR2</i>)	Codominant					
	GG	33	35	11		
	GA	17	35	15	2.14 (0.92-4.94); 0.028	9.55 (1.53-59.47)
	AA	2	0	6		6.41 (0.47-87.80); 0.019
	Dominant					
	GG	33	35	11		
	GA+AA	19	35	21	1.85 (0.82-4.19); 0.134	8.65 (1.60-46.68); 0.005 †
	Recessive					
	GG+GA	50	70	26		
	AA	2	0	6	0; 0.049	2.64 (0.27-26.06); 0.401
Over-dominant						
GG+AA	35	35	17	2.29 (1.00-5.26); 0.046	6.99 (1.26-38.86); 0.015	

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

	GA	17	35	15		
	Additive					
		52	70	32	1.44 (0.67-3.07); 0.342	3.92 (1.17-13.10); 0.015

† Best model to explain the association according to the Akaike information criterion. The odds ratios and the P values were from logistic regression models adjusted for age, gender, smoking history, history of hypertension, diabetes mellitus, and coronary artery disease. After Bonferroni correction a P-value < 0.025 was considered significant.

Table 5: Association of *IFNAR2* rs2236757 and *OAS3* rs10735079 polymorphisms with COVID-19 signs and symptoms in all patients

rs2236757 (<i>IFNAR2</i>)		Yes	No	OR (95% CI)	P-value	rs10735079 (<i>OAS3</i>)		Yes	No	OR (95% CI)	P-value
Sore throat	Codominant †					Sore throat	Codominant				
	GG	13	32				GG	15	17	0.88 (0.33-2.38)	
	GA	23	25	2.52 (1.02-6.24)	0.011		GA	17	20	0.16 (0.04-0.58)	0.004
	AA	0	6	0			AA	4	26		
	Dominant						Dominant				
	GG	13	32				GG	15	17		
	GA+AA	23	31	1.98 (0.82-4.76)	0.124		GA+AA	21	46	0.47 (0.19-1.16)	0.099
	Recessive						Recessive †				
	GG+GA	36	57				GG+GA	32	37		
	AA	0	6	0	0.026		AA	4	26	0.17 (0.05-0.55)	< 0.001
	Over-dominant						Over-dominant				
	GG+AA	13	38				GG+AA	19	43		
	GA	23	25	2.89 (1.18-7.13)	0.018		GA	17	20	1.86 (0.78-4.45)	0.162
Log-Additive					Log-Additive						
	36	63	1.25 (0.61-2.57)	0.538		36	63	0.44 (0.24-0.79)	0.004		

	Dyspnea					Muscle aches	Muscle aches				
Dyspnea	Codominant					Muscle aches	Codominant				
	GG	16	29				GG	22	10		
	GA	29	20	4.28 (1.57-11.71)	0.002		GA	27	11	1.11 (0.38-3.22)	0.079
	AA	6	0	0			AA	14	16	0.36 (0.12-1.09)	
	Dominant						Dominant				
	GG	16	29				GG	22	10		
	GA+AA	35	20	4.81 (1.77-13.09)	0.001		GA+AA	41	27	0.67 (0.26-1.70)	0.394
	Recessive						Recessive †				
	GG+GA	45	49	0	0.054		GG+GA	49	21		
	AA	6	0				AA	14	16	0.34 (0.13-0.88)	0.0248
	Over-dominant						Over-dominant				
	GG+AA	22	29				GG+AA	36	26		
	GA	29	20	3.49 (1.32-9.25)	0.009		GA	27	11	1.81 (0.74-4.47)	0.191
	Log-Additive †						Log-Additive				
		51	49	4.70 (1.80-12.27)	< 0.001			63	37	0.60 (0.34-1.05)	0.068

† Best model to explain the association according to the Akaike information criterion. The odds ratios and the P values were from logistic regression models adjusted for age, gender, smoking history, history of hypertension, diabetes mellitus, and coronary artery disease. After Bonferroni correction a P-value < 0.025 was considered significant

Table 6: Association of *IFNAR2* rs2236757 and *OAS3* rs10735079 polymorphisms with COVID-19 signs and symptoms in the community patients and ICU patients, separately

			Yes	No	OR (95% CI)	P-value	
Community patients	rs2236757 (IFNAR2)	Loss of taste/smell	Codominant				
			GG	18	17		
			GA	27	7	3.57 (1.19-10.72)	0.019
			AA	0	0		
		Muscle aches	Codominant				
			GG	17	18		
			GA	25	9	3.65 (1.12-11.86)	0.0254
			AA	0	0		
		Dyspnea	Codominant				
	GG		8	27			
	GA		16	18	4.84 (1.45-16.13)	0.006	
		AA	0	0			
rs10735079 (OAS3)	Sore throat	Codominant					
		GG	9	10			
		GA	15	15	1.13 (0.33-3.89)	0.042	
		AA	3	17	0.21 (0.04-1.01)		

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

				Yes	No	OR (95% CI)	P-value	
		Dominant						
		GG	9	10				
		GA+AA	18	32	0.62 (0.20-1.93)		0.408	
		Recessive †						
		GG+GA	24	25				
		AA	3	17	0.19 (0.05-0.79)		0.012	
		Over-dominant						
		GG+AA	12	27				
		GA	15	15	2.21 (0.76-6.45)		0.143	
		Log-Additive						
			27	42	0.50 (0.24-1.02)		0.051	
ICU patients	rs10735079 (OAS3)	Muscle aches	Codominant					
			GG	11	2			
			GA	6	2	0.26 (0.01-5.08)		0.042
			AA	4	6	0.05 (0.00-1.06)		
			Dominant					
			GG	11	2			
			GA+AA	10	8	0.11 (0.01-1.41)		0.046
			Recessive					
			GG+GA	17	4			
			AA	4	6	0.11 (0.01-0.91)		0.023
			Over-dominant					
			GG+AA	15	8			
			GA	6	2	1.48 (0.20-10.84)		0.698
Log-Additive †								
	21	10	0.22 (0.05-0.99)		0.014			

† Best model to explain the association according to the Akaike information criterion. The odds ratios and the P values were from logistic regression models adjusted for age, gender, smoking history, history of hypertension, diabetes mellitus, and coronary artery disease. After Bonferroni correction a P-value < 0.025 was considered significant.